Generate Biomedicines Inc(GENB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 7:30 PM ET (Korea 9/11 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 57.05% | Shs Outstand | 128.3M | Perf Week | -5.47% |
| Market Cap | 1.98B | Forward P/E | - | EPS next Y | -0.73% | Insider Trans | - | Shs Float | 55.1M | Perf Month | 7.85% |
| Enterprise Value | 1.58B | PEG | - | EPS next Q | -0.56 | Inst Own | 25.09% | Short Float | 13.22% | Perf Quarter | 16.95% |
| Income | - | P/S | - | EPS this Y | 49.87% | Inst Trans | 6.8% | Short Ratio | 7.24 | Perf Half Y | 20.99% |
| Sales | - | P/B | 4.33 | EPS next 5Y | 26.8% | ROA | - | Short Interest | 7.29M | Perf YTD | 2.6% |
| Book/sh | 3.56 | P/C | 4.32 | EPS past 3/5Y | - | ROE | - | 52W High | -32.11% ($22.67) | Perf Year | - |
| Cash/sh | 3.56 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 39.91% ($11.00) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 5.57% 9% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.28 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.3 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 47.94 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.3 | Sales Q/Q | - | SMA20 | -4.92% ($16.19) | Beta | - | Target Price | $27 |
| Payout | - | Debt/Eq | 0.14 | Earnings | 2026/8/6 | SMA50 | 1.39% ($15.18) | Rel Volume | 1 | Prev Close | $15.52 |
| Employees | 312 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | -2.3% 19.13% | SMA200 | 10.26% ($13.96) | Avg Volume(3M) | 1.01M | Price | $15.39 |
| IPO | 2026/2/27 | Option/Short | No/Yes | Trades | 9359 | Volume | 1,007,504 | Change | -0.84% |
Company
GENB is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US biotech company that operates a generative AI-based drug discovery platform. It leverages a generative AI platform that designs proteins and antibodies to discover and develop therapeutics targeting a wide range of diseases, maintaining a pipeline across multiple therapeutic areas. The company stands out as a differentiated biotech by combining its generative AI drug discovery platform with its pipeline.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
GENB makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +49.9% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 25.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ARKG 0.01%
RESM 0.00%
IWO 0.00%
ONEQ 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $2B.
GENB $2B PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is GENB?
GENB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GENB?
The market cap of GENB is approximately $2.0B, ranking 2,112 within its sector.
What is the 52-week high and low for GENB?
GENB has recorded a 52-week high of $22.67 and a low of $11.00.
